Table 1

Clinical characteristics of the patients at diagnosis

n

34

Gender (M:F)

17:17 (ratio 1:1)

Age (years)

55.7 ± 17 (range 25–80 years)

ANCA (yes: no)

26:8 (ratio 3,25:1)

Type of ANCA (MPO: PR3)

17:9 (ratio 1,9:1)

Extrarenal manifestations

23 (67.6%)

Respiratory system

19 (55.9%)

Joints

12 (35.3%)

Gastrointestinal system

7 (20.6%)

Skin

5 (14.7%)

Muscles

2 (5.9%)

Genitourinary system

1 (2.9%)

Liver

1 (2.9%)

Plasma creatinine (mg/dl)

6 ± 4.2 (range 0.8–19.4 mg/dl)

Proteinuria (g/24 h)

1.4 ± 0.96 (range 0.2–4.85 g/24 h)

CRP (mg/l)

72.8 ± 78 (range 3.4–272 mg/dl)

Oligoanuria

11 (32.3%)

Dialysis

14 (41.2%)

Plasma exchange

14 (41.2%)

Follow-up (months)

20 ± 22 (range 1–72 months)


Abbrev: MPO, myeloperoxidase; PR3, Proteinase 3; CRP, C-reactive protein

Alexopoulos et al. BMC Nephrology 2006 7:16   doi:10.1186/1471-2369-7-16

Open Data